Sanofi 주식 가격. SAN - 주식 시세, 차트, 과거 거래, 주식 채팅, 재무.

실시간 토론 및 거래 아이디어: 강력한 플랫폼으로 자신있게 거래하세요.

프리미엄

가격

101.86

매수가

101.50

매도가

102.00

거래량

1,657,302

101.26 일간 변동폭 102.72

84.93 52주 범위 106.14

market_cap

127.594B

전일 종가

101.72

개장가

101.40

최근 거래 시간

2720

101.86

마지막 거래 시간

재정 규모

VWAP

평균 볼륨(3m)

1,570,828

발행 주식

1,252,640,466

배당수익률

10.88%

주가수익률

23.63

주당순이익(EPS)

4.31

매출

43.07B

순이익

5.4B

섹터

Health & Allied Services,nec

산업

Pharmaceutical Preparations

웹사이트

www.sanofi.com

본부

Paris, Paris, Fra

설립됨

1994

Sanofi is listed in the Health & Allied Services sector of the 유로넥스트 (Euronext) with ticker SAN. The last closing price for Sanofi was 101.72 €. Over the last year, Sanofi shares have traded in a share price range of 84.93 € to 106.14 €.

Sanofi currently has 1,252,640,466 shares in issue. The market capitalisation of Sanofi is 127.42 € billion. Sanofi has a price to earnings ratio (PE ratio) of 23.63.

Communiqué de presse : Approbation du Sarclisa dans l’UE – premier anti-CD38 en association avec le schéma VRd de référence pour le traitement du myélome multiple nouvellement diagnostiqué de l’adulte non éligible à une greffe

Communiqué de presse : Approbation du Sarclisa dans l’UE – premier anti-CD38 en association avec le schéma VRd de référence pour le traitement du myélome multiple nouvellement diagnostiqué de...

Press Release: Sarclisa approved in the EU as the first anti-CD38 therapy in combination with standard-of-care VRd to treat transplant-ineligible newly diagnosed multiple myeloma

Press Release: Sarclisa approved in the EU as the first anti-CD38 therapy in combination with standard-of-care VRd to treat transplant-ineligible newly diagnosed multiple myeloma Sarclisa approved...

Press Release: Sarclisa approved in the EU as the first anti-CD38 therapy in combination with standard-of-care VRd to treat transplant-ineligible newly diagnosed multiple myeloma

Sarclisa approved in the EU as the first anti-CD38 therapy in combination with standard-of-care VRd to treat transplant-ineligible newly diagnosed multiple myeloma Approval is based on positive...

Communiqué de presse : Opella : étape clé franchie pour l’étude consacrée au Cialis

Communiqué de presse : Opella : étape clé franchie pour l’étude consacrée au Cialis Opella : étape clé franchie pour l’étude consacrée au Cialis Paris, le 21 janvier 2025. Opella, l’activité Santé...

Press Release: Opella reaches study milestone for Cialis

Press Release: Opella reaches study milestone for Cialis Opella reaches study milestone for Cialis Paris, January 21, 2025. Opella, Sanofi’s Consumer Healthcare business, announced that the US...

Press Release: Opella reaches study milestone for Cialis

Opella reaches study milestone for Cialis Paris, January 21, 2025. Opella, Sanofi’s Consumer Healthcare business, announced that the US Food and Drug Administration (FDA) has lifted a clinical...

Sanofi: Information concerning the total number of voting rights and shares – November 2024

Sanofi: Information concerning the total number of voting rights and shares – November 2024 Information concerning the total number of voting rights and shares, provided pursuant to article L...

Sanofi: Informations relatives au nombre de droits de vote et d'actions - Novembre 2024

Sanofi: Informations relatives au nombre de droits de vote et d'actions - Novembre 2024 Informations relatives au nombre total de droits de vote et d’actions prévues par l’article L. 233-8 II...

Press Release: Sarclisa obtains first approval in China for the treatment of adult patients with relapsed or refractory multiple myeloma

Sarclisa obtains first approval in China for the treatment of adult patients with relapsed or refractory multiple myeloma Approval based on positive pivotal ICARIA-MM phase 3 study using the...

Press Release: New Sarclisa subcutaneous formulation met co-primary endpoints in the IRAKLIA phase 3 study in multiple myeloma

Press Release: New Sarclisa subcutaneous formulation met co-primary endpoints in the IRAKLIA phase 3 study in multiple myeloma New Sarclisa subcutaneous formulation met co-primary endpoints in the...

기간	변동	변동 %	시가	고가	저가	평균 일일 거래량	VWAP
1	2.32	2.33072131806	99.54	103.24	99	1598000	100.83150736	DE
4	8.91	9.58579881657	92.95	103.24	92.84	1504843	97.23899417	DE
12	4.96	5.11867905057	96.9	103.24	87.5	1570828	93.75962248	DE
26	5.3	5.48881524441	96.56	106.14	87.5	1493635	97.40878922	DE
52	9.28	10.0237632318	92.58	106.14	84.93	1465935	93.56565	DE
156	7.79	8.28106729032	94.07	106.66	76.45	1726655	92.87497768	DE
260	14.43	16.5046322773	87.43	106.66	67.65	1930093	89.48545395	DE

SAN - Frequently Asked Questions (FAQ)

What is the current Sanofi share price?

The current share price of Sanofi is 101.86 €

How many Sanofi shares are in issue?

Sanofi has 1,252,640,466 shares in issue

What is the market cap of Sanofi?

The market capitalisation of Sanofi is EUR 127.42B

What is the 1 year trading range for Sanofi share price?

Sanofi has traded in the range of 84.93 € to 106.14 € during the past year

What is the PE ratio of Sanofi?

The price to earnings ratio of Sanofi is 23.63

What is the cash to sales ratio of Sanofi?

The cash to sales ratio of Sanofi is 2.96

What is the reporting currency for Sanofi?

Sanofi reports financial results in EUR

What is the latest annual turnover for Sanofi?

The latest annual turnover of Sanofi is EUR 43.07B

What is the latest annual profit for Sanofi?

The latest annual profit of Sanofi is EUR 5.4B

What is the registered address of Sanofi?

The registered address for Sanofi is 46, AVENUE DE LA GRANDE ARMEE, PARIS, PARIS, 75017

What is the Sanofi website address?

The website address for Sanofi is www.sanofi.com

Which industry sector does Sanofi operate in?

Sanofi operates in the PHARMACEUTICAL PREPARATIONS sector

가장 활성
% 상승자
% 패자

기호	가격	볼륨
NICBSNicox SA	0.0264 € (45.86%)	198
ALENTEntreparticuliersCom	0.578 € (28.44%)	16.94k
FPGUnion Tech Info	0.344 € (28.36%)	126.15k
MLOCTOctopus Biosafety	0.178 € (27.14%)	3.89k
ALDVAlliance Developpement Capital Siic	0.0695 € (25.23%)	10k
BIODSBiosynex DS	0.0278 € (-30.50%)	72.52k
MLCLPColipays	1.06 € (-25.87%)	74
ALVERVergnet	0.001 € (-23.08%)	79.31M
MLSTRStreit Mecanique	7.70 € (-19.79%)	20
MLSRPSpeed Rabbit Pizza	13.20 € (-18.52%)	91
ATOAtos SE	0.0021 € (0.00%)	599.35M
ALVERVergnet	0.001 € (-23.08%)	79.31M
BCPBanco Comercial Portugues SA	0.5086 € (1.64%)	48.29M
ALHPIHopium SA	0.0031 € (-6.06%)	27.89M
ALNRGEnergisme SA	0.0044 € (0.00%)	24.22M